Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Geniculate Artery Embolization for Recurrent Effusion After Total Knee Arthroplasty in a Patient With Hemophilia.

Cureus·2026
Same author

Emergency mitral valve transcatheter edge-to-edge repair in cardiogenic shock due to papillary muscle rupture.

Journal of cardiology cases·2026
Same author

Stem Cell and Cell-Free Strategies for Osteoarthritis: Toward Durable Regenerative Therapies.

Stem cells international·2026
Same author

Control of cell division by an <i>Acinetobacter baumannii</i> protein with a novel nucleotidyl-cyclase-like fold.

bioRxiv : the preprint server for biology·2026
Same author

Survival Outcomes of Cabazitaxel or Subsequent Androgen Receptor Pathway Inhibitor (ARPI) in Post-Docetaxel/ARPI Metastatic Castration-Resistant Prostate Cancer.

Clinical genitourinary cancer·2026
Same author

Urgent Transcatheter Edge-To-Edge Mitral Valve Repair in Cardiogenic Shock: A Case Series.

A&A practice·2026
Same journal

Eugene Braunwald, MD, 1929-2026.

Circulation·2026
Same journal

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Circulation·2026
Same journal

Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry.

Circulation·2026
Same journal

Heart Failure Occurring in the Perinatal Period: A Scientific Statement From the American Heart Association.

Circulation·2026
Same journal

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same journal

Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

Circulation·2026
查看所有相关文章

相关实验视频

Updated: May 13, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

通过基于多模式细胞的基因疗法最大限度地提高心室功能.

Terrence M Yau1, Christopher Kim, Guangming Li

  • 1Division of Cardiovascular Surgery, Toronto General Hospital, Department of Surgery, University of Toronto, Heart & Stroke Foundation/Richard Lewar Centre of Excellence, Toronto, Ontario, Canada. terry.yau@utoronto.ca

Circulation
|September 15, 2005
PubMed
概括
此摘要是机器生成的。

这项研究表明,将血管内皮生长因子 (VEGF) 和胰岛素样生长因子I (IGF-I) 基因治疗与骨髓细胞 (BMC) 移植相结合,可以改善心脏功能. 这种多模式的方法提高了细胞存活率,并减少了心肌痕的细胞死亡.

更多相关视频

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

相关实验视频

Last Updated: May 13, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

科学领域:

  • 心血管研究研究心血管研究
  • 再生医学是一种再生医学.
  • 基因治疗 基因治疗

背景情况:

  • 血管内皮生长因子 (VEGF) 在心肌痕中增强血管生成.
  • 胰岛素样生长因子I (IGF-I) 可能会促进缩并抑制亡.
  • 骨髓细胞 (BMC) 移植是治疗心脏损伤的潜在疗法.

研究的目的:

  • 评估基于细胞的IGF-I和VEGF多基因疗法的疗效.
  • 评估对左心室 (LV) 功能,细胞存活率和细胞亡的影响.
  • 在大鼠心肌梗塞模型中确定BMC移植后的益处.

主要方法:

  • 患有诱导心肌梗塞的易斯大鼠接受了经过工程设计的BMC来表达VEGF,IGF-I或两者.
  • 在4周内量化了基因表达,细胞存活率,细胞亡和LV功能.
  • 技术包括实时PCR,TUNEL染色,心声回声和西部斑点.

主要成果:

  • 在BMC中VEGF和IGF-I的同时表达显著增加了痕组织中的IGF-I和VEGF水平.
  • 在VEGF+IGF-I组中,移植细胞的存活率最高.
  • 与对照组和单基因疗法组相比,联合基因疗法组的亡减少,LV射出分数显著改善.

结论:

  • 移植表达VEGF和IGF-I的BMC有效地减少了细胞亡,并提高了移植细胞的存活率.
  • 这种多模式的基于细胞的基因疗法方法最大限度地提高了心肌梗塞后的左心室功能恢复.
  • 结合基因疗法有望改善心脏病细胞移植策略的结果.